poisar

Stocks · News reference

NewcelX Ltd. Enters Binding Term Sheet to Divest Legacy Mazindol Portfolio

NewcelX Ltd. has agreed to divest its worldwide Mazindol asset portfolio to REA Holdings Inc. in a deal involving upfront cash, equity, and potential milestone payments.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NCEL
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments

    NewcelX Ltd. (Nasdaq: NCEL) announced a binding term sheet to divest its Mazindol asset portfolio to REA Holdings Inc. for $500,000 upfront ($30,000 cash and $470,000 in equity representing 9.4% stake), plus up to $55 million in potential milestone payments and tiered royalties of 2-8% on global net sales. The divestiture allows NewcelX to focus on its core cell-therapy pipeline for Type 1 Diabetes while preserving potential value for CVR holders.

    NCEL